Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

of Plavix((R)), Myslee((R)) and Allegra((R)), despite the sales growth comparison being subdued by the fact that the 2008 second-quarter comparative included sales of the active ingredient of Aprovel((R)) to our local partners. Latin America, where net sales rose by 5.7%, was boosted by the acquisition of Medley. However, our performance in Brazil and Mexico was adversely affected by the economic situation, which led to inventory rundowns of some products in distribution channels. First-half net sales in the Other Countries region were up 9.4%, with Japan and China reporting growth of 10.2% (to euro 952 million) and 35.1% (to euro 259 million) respectively.

Second-quarter net sales in emerging markets(5) were euro 1,855 million, an increase of 20.1% (or 6.3% on a constant structure basis and at constant exchange rates). First-half emerging-market net sales were 14.1% higher at euro 3,470 million.

(5) World excluding North America, Western Europe (France, Germany, United Kingdom, Italy, Spain, Greece, Cyprus, Malta, Belgium, Portugal, Netherlands, Austria, Switzerland, Ireland, Finland, Norway, Iceland, Denmark), Japan, Australia and New Zealand.

Very strong results due to sales growth and tight cost control

2009 second-quarter financial results

Adjusted income statement excluding selected items

Sanofi-aventis generated second-quarter net sales of euro 7,438 million, up 11.2% on a reported basis. "Other revenues" rose by 25.5%, reflecting a good performance by Plavix((R)) in the United States and the appreciation of the U.S. dollar.

Gross profit came to euro 5,964 million, an increase of 13.6%, or of 7.0% at constant exchange rates. The ratio of cost of sales to net sales improved by 1.2 points to 24.6%, mainly due to the effect of exchange rates.


'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... - Continued Advancement Toward ...   Shire (LSE: SHP, NASDAQ: SHPG ... March 31, 2015. Financial Highlights Q1 ... Total revenues $1,488 million +11% +15% Non GAAP operating ... from continuing operations $475 million +55% Non GAAP EBITDA ...
(Date:4/30/2015)... 2015 SureClinical, a leader in cloud-based ... has joined SureClinical’s executive team as Chief Financial Officer. ... technology executive with over 25 years in leadership roles ... , Ms. Morris joins SureClinical from Marrone Bio Innovations ... CFO of MBI from its founding in 2006 until ...
(Date:4/29/2015)... 29, 2015 SPIE DSS, ... on the East Coast, reaffirmed its value last week ... developers, and industry suppliers to meet and advance the ... applications. , The event included 55 conferences in two ... sensing and imaging -- and an exhibition showcasing 382 ...
(Date:4/29/2015)... CENTENNIAL, Colo. , April 29, 2015 /PRNewswire-USNewswire/ ... largest providers of cartilage, cellular, bone, skin and ... wound care to advance patient healing, announced the ... The Centers for Medicare & Medicaid Services (CMS) ... graft, from the low-cost to the high-cost category ...
Breaking Biology Technology:Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Julie I. Morris Joins SureClinical as Chief Financial Officer 2SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4AlloSource Announces New Possibilities In Wound Care 2
... Inc. (Nasdaq: MEDX ) announced today that ... be the subject of poster presentations at the Annual ... being held April 18-22, 2009 in Colorado:, ... "A Phase I, open-label, dose-escalation, multi-dose study of MDX-1401 ...
... Symbol: MSEDMONTON, March 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today announced financial and operational results ... has demonstrated the ability to safely affect MS progression ... results of the Canadian/European trial (MAESTRO-01) in the second ...
... Patents in Each of the Three Critical Areas of ... Corporation, a leading developer of targeted, systemic RNA interference ... and Trademark Office (USPTO) has issued the company a ... of a potent small interfering RNA (siRNA) sequence. ...
Cached Biology Technology:Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research 2BioMS Medical Announces 2008 Year End Results 2BioMS Medical Announces 2008 Year End Results 3BioMS Medical Announces 2008 Year End Results 4BioMS Medical Announces 2008 Year End Results 5BioMS Medical Announces 2008 Year End Results 6BioMS Medical Announces 2008 Year End Results 7BioMS Medical Announces 2008 Year End Results 8BioMS Medical Announces 2008 Year End Results 9BioMS Medical Announces 2008 Year End Results 10BioMS Medical Announces 2008 Year End Results 11Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence 2
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
(Date:3/31/2015)... YORK , March 31, 2015   Guidepoint ... the launch of the Post-Surgical Pain Management TRACKER, part ... products tracking usage trends in the medical device and ... access to data including treatment volumes, market share, and ... the pain associated with joint surgery. The ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Inc. (NASDAQ: AWRE ), a leading supplier of ... announced that Edmund C. Reiter has resigned, effective April 1, ... the board of the company citing personal reasons.   ... Counsel have been named co-CEOs and co-Presidents on an interim ...
... 2011 The Center for Engineering in Medicine (CEM) ... Hospital (MGH), a Harvard Teaching Hospital -- has announced ... in conjunction with event organizer Horizon House Ltd.  The ... School on July 14-15, and expects to draw over ...
... MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, ... bioimplants processed from human amniotic membrane, announced today the ... biologic implant specifically processed to offer a wide variety ... also announces the hiring of Frank Burrows as its ...
Cached Biology News:Aware, Inc. Announces Resignation of Chief Executive Officer 2Aware, Inc. Announces Resignation of Chief Executive Officer 3Massachusetts General Hospital Center Reignites Methods in Bioengineering Conference 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 3MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 4
... The Varian 500-MS LC Ion Trap ... high-throughput LC/MS analysis where sensitivity, reliability ... 500-MS provides a robust platform for ... mass resolution, and mass stability reflect ...
... Ventilates and removes chemical ... of exhaust. Bonded charcoal filters ... impellers ensure safe exhaust flow ... 15" access opening. Includes air ...
... benchtop ductless exhaust hood ventilates and ... indoor release of exhaust. Bonded charcoal ... 28" of vertical clearance (with access ... polypropylene spill tray; options include final ...
...
Biology Products: